Publications by authors named "M Plander"
Background: Myelodysplastic neoplasms (MDS) are characterized by cytopenia, morphologic dysplasia, and genetic abnormalities. Multiparameter flow cytometry (FCM) is recommended in the diagnostic work-up of suspected MDS, but alone is not sufficient to establish the diagnosis. Our aim was to investigate the diagnostic power of FCM in a heterogeneous population of patients with cytopenia, excluding cases with increased blast count.
View Article and Find Full Text PDFArticle Synopsis
- TP53 mutations are linked to chemoresistance in chronic lymphocytic leukaemia (CLL) and can indicate the ineffectiveness of standard chemoimmunotherapy, prompting a need for better mutation assessment.* -
- In a study of 901 CLL patients, 17.5% had TP53 mutations, with nearly half being low-burden mutations, which raises questions about their clinical significance.* -
- Low-burden TP53 mutations led to earlier treatment initiation compared to patients without mutations, suggesting the need to reconsider the detection threshold for these mutations in diagnostics.*
Background And Purpose:
Using patient registries is essential both in clinical research and in medical practice. Headaches, more specifically migraines are one of the most common complaints that can detract the quality of a patient’s life and these complaints also have a significant socio-economic effect. Our goal is to create a national Headache Registry and to also provide the pre-analysis of the registry’s database.
View Article and Find Full Text PDFBackground: Recent genomic studies revealed enhancer of zeste homolog 2 (EZH2) gain-of-function mutations, representing novel therapeutic targets in follicular lymphoma (FL) in around one quarter of patients. However, these analyses relied on single-site tissue biopsies and did not investigate the spatial heterogeneity and temporal dynamics of these alterations.
Objectives: We aimed to perform a systematic analysis of EZH2 mutations using paired tissue (tumor biopsies [TB]) and liquid biopsies (LB) collected prior to treatment within the framework of a nationwide multicentric study.
The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common mutations G101V and D103Y, sensitive (10) screening for the most common mutations G101V and D103Y was performed in 67 R/R CLL patients during venetoclax single-agent or venetoclax-rituximab combination therapy.
View Article and Find Full Text PDF